Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity

T. C. Wascher, W. F. Graier, P. Dittrich, Mehboob Hussain, B. Bahadori, S. Wallner, H. Toplak

Research output: Contribution to journalArticle

Abstract

The present study was carded out to evaluate the effect of a low-dose intravenous supplementation of L-arginine on insulin-mediated vasodilatation and insulin sensitivity. The study was performed in healthy subjects (n = 7) and patients with obesity (n = 9) and non-insulin-dependent diabetes mellitus (NIDDM) (n = 9). Insulin-mediated vasodilatation was measured by venous occlusion plethysmography during the insulin suppression test, evaluating insulin sensitivity. Experiments were performed twice in each subject in the presence or absence of a concomitant infusion of L-arginine (0.52 mg kg-1 min-1). L-Arginine restored the impaired insulin-mediated vasodilatation observed in obesity (22.4 ± 4.1%, P <0.01 vs. without L-arginine) and NIDDM (20.3 ± 3.2%, P <0.01 vs. without L-arginine). In healthy subjects, no effect on insulin mediated-vasodilatation was observed (24.8 ± 3.1% vs. 21.4 ± 3.1%). Insulin sensitivity was improved significantly (P <0.001) in all three groups by infusion of L-arginine. No effect of L-arginine was observed on insulin, insulin-like growth factor I (IGF-I), free fatty acids (FFAs) or C-peptide levels during the insulin suppression test. Our data indicate that defective insulin-mediated vasodilatation in obesity and NIDDM can be normalized by intravenous L-arginine. Furthermore, L-arginine improves insulin sensitivity in obese patients and NIDDM patients as well as in healthy subjects, indicating a possible mechanism that is different from the restoration of insulin-mediated vasodilatation.

Original languageEnglish (US)
Pages (from-to)690-695
Number of pages6
JournalEuropean Journal of Clinical Investigation
Volume27
Issue number8
StatePublished - 1997
Externally publishedYes

Fingerprint

Vasodilation
Arginine
Insulin Resistance
Insulin
Type 2 Diabetes Mellitus
Medical problems
Healthy Volunteers
Obesity
Plethysmography
C-Peptide
Insulin-Like Growth Factor I
Nonesterified Fatty Acids
Restoration

Keywords

  • Endothelial dysfunction
  • Insulin sensitivity
  • Insulin-mediated vasodilatation
  • L-Arginine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wascher, T. C., Graier, W. F., Dittrich, P., Hussain, M., Bahadori, B., Wallner, S., & Toplak, H. (1997). Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity. European Journal of Clinical Investigation, 27(8), 690-695.

Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity. / Wascher, T. C.; Graier, W. F.; Dittrich, P.; Hussain, Mehboob; Bahadori, B.; Wallner, S.; Toplak, H.

In: European Journal of Clinical Investigation, Vol. 27, No. 8, 1997, p. 690-695.

Research output: Contribution to journalArticle

Wascher, TC, Graier, WF, Dittrich, P, Hussain, M, Bahadori, B, Wallner, S & Toplak, H 1997, 'Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity', European Journal of Clinical Investigation, vol. 27, no. 8, pp. 690-695.
Wascher, T. C. ; Graier, W. F. ; Dittrich, P. ; Hussain, Mehboob ; Bahadori, B. ; Wallner, S. ; Toplak, H. / Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity. In: European Journal of Clinical Investigation. 1997 ; Vol. 27, No. 8. pp. 690-695.
@article{25dda24cbee4470fade51b0e6ed20cf8,
title = "Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity",
abstract = "The present study was carded out to evaluate the effect of a low-dose intravenous supplementation of L-arginine on insulin-mediated vasodilatation and insulin sensitivity. The study was performed in healthy subjects (n = 7) and patients with obesity (n = 9) and non-insulin-dependent diabetes mellitus (NIDDM) (n = 9). Insulin-mediated vasodilatation was measured by venous occlusion plethysmography during the insulin suppression test, evaluating insulin sensitivity. Experiments were performed twice in each subject in the presence or absence of a concomitant infusion of L-arginine (0.52 mg kg-1 min-1). L-Arginine restored the impaired insulin-mediated vasodilatation observed in obesity (22.4 ± 4.1{\%}, P <0.01 vs. without L-arginine) and NIDDM (20.3 ± 3.2{\%}, P <0.01 vs. without L-arginine). In healthy subjects, no effect on insulin mediated-vasodilatation was observed (24.8 ± 3.1{\%} vs. 21.4 ± 3.1{\%}). Insulin sensitivity was improved significantly (P <0.001) in all three groups by infusion of L-arginine. No effect of L-arginine was observed on insulin, insulin-like growth factor I (IGF-I), free fatty acids (FFAs) or C-peptide levels during the insulin suppression test. Our data indicate that defective insulin-mediated vasodilatation in obesity and NIDDM can be normalized by intravenous L-arginine. Furthermore, L-arginine improves insulin sensitivity in obese patients and NIDDM patients as well as in healthy subjects, indicating a possible mechanism that is different from the restoration of insulin-mediated vasodilatation.",
keywords = "Endothelial dysfunction, Insulin sensitivity, Insulin-mediated vasodilatation, L-Arginine",
author = "Wascher, {T. C.} and Graier, {W. F.} and P. Dittrich and Mehboob Hussain and B. Bahadori and S. Wallner and H. Toplak",
year = "1997",
language = "English (US)",
volume = "27",
pages = "690--695",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity

AU - Wascher, T. C.

AU - Graier, W. F.

AU - Dittrich, P.

AU - Hussain, Mehboob

AU - Bahadori, B.

AU - Wallner, S.

AU - Toplak, H.

PY - 1997

Y1 - 1997

N2 - The present study was carded out to evaluate the effect of a low-dose intravenous supplementation of L-arginine on insulin-mediated vasodilatation and insulin sensitivity. The study was performed in healthy subjects (n = 7) and patients with obesity (n = 9) and non-insulin-dependent diabetes mellitus (NIDDM) (n = 9). Insulin-mediated vasodilatation was measured by venous occlusion plethysmography during the insulin suppression test, evaluating insulin sensitivity. Experiments were performed twice in each subject in the presence or absence of a concomitant infusion of L-arginine (0.52 mg kg-1 min-1). L-Arginine restored the impaired insulin-mediated vasodilatation observed in obesity (22.4 ± 4.1%, P <0.01 vs. without L-arginine) and NIDDM (20.3 ± 3.2%, P <0.01 vs. without L-arginine). In healthy subjects, no effect on insulin mediated-vasodilatation was observed (24.8 ± 3.1% vs. 21.4 ± 3.1%). Insulin sensitivity was improved significantly (P <0.001) in all three groups by infusion of L-arginine. No effect of L-arginine was observed on insulin, insulin-like growth factor I (IGF-I), free fatty acids (FFAs) or C-peptide levels during the insulin suppression test. Our data indicate that defective insulin-mediated vasodilatation in obesity and NIDDM can be normalized by intravenous L-arginine. Furthermore, L-arginine improves insulin sensitivity in obese patients and NIDDM patients as well as in healthy subjects, indicating a possible mechanism that is different from the restoration of insulin-mediated vasodilatation.

AB - The present study was carded out to evaluate the effect of a low-dose intravenous supplementation of L-arginine on insulin-mediated vasodilatation and insulin sensitivity. The study was performed in healthy subjects (n = 7) and patients with obesity (n = 9) and non-insulin-dependent diabetes mellitus (NIDDM) (n = 9). Insulin-mediated vasodilatation was measured by venous occlusion plethysmography during the insulin suppression test, evaluating insulin sensitivity. Experiments were performed twice in each subject in the presence or absence of a concomitant infusion of L-arginine (0.52 mg kg-1 min-1). L-Arginine restored the impaired insulin-mediated vasodilatation observed in obesity (22.4 ± 4.1%, P <0.01 vs. without L-arginine) and NIDDM (20.3 ± 3.2%, P <0.01 vs. without L-arginine). In healthy subjects, no effect on insulin mediated-vasodilatation was observed (24.8 ± 3.1% vs. 21.4 ± 3.1%). Insulin sensitivity was improved significantly (P <0.001) in all three groups by infusion of L-arginine. No effect of L-arginine was observed on insulin, insulin-like growth factor I (IGF-I), free fatty acids (FFAs) or C-peptide levels during the insulin suppression test. Our data indicate that defective insulin-mediated vasodilatation in obesity and NIDDM can be normalized by intravenous L-arginine. Furthermore, L-arginine improves insulin sensitivity in obese patients and NIDDM patients as well as in healthy subjects, indicating a possible mechanism that is different from the restoration of insulin-mediated vasodilatation.

KW - Endothelial dysfunction

KW - Insulin sensitivity

KW - Insulin-mediated vasodilatation

KW - L-Arginine

UR - http://www.scopus.com/inward/record.url?scp=0030879928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030879928&partnerID=8YFLogxK

M3 - Article

C2 - 9279534

AN - SCOPUS:0030879928

VL - 27

SP - 690

EP - 695

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 8

ER -